BIOXCEL THERAPEUT DL-,001 WKN: A2JF20 ISIN: US09075P1057 Kürzel: BTAI Forum: Aktien Thema: Hauptdiskussion

Ich denke der Kurs wird halten, bin jedoch wieder Mal raus. 😅

Wünsche euch viel Glück

hab noch 1,9 % vor mir ich glaub es selber kaum 😂

Noch 4% bis Ek 🥳😂

Der Tag ist lang

RSI ist im neutralen Bereich, Dip bleibt vermutlich aus.

Bin raus mit 13 K Anteilen, 600 Euro plus warte auf dip

2,80 Euro 👌

Was ist hier los, steigt ja.....

Wir haben ja kaum Volumen.

Vielleicht wird es heute wieder die 3,09$

2.74 mein ek :-)

Nächster Halt würde ich auf 2,96$ schätzen

Ram Selvaraju has given his Buy rating due to a combination of factors related to BioXcel Therapeutics’ progress and prospects. The company’s flagship product, BXCL501, has demonstrated robust efficacy in prior studies for the acute treatment of agitation in adults with schizophrenia or bipolar disorders, which has led to its FDA approval and market release under the name IGALMI™ at a healthcare provider’s supervision. The prospect of expanding its use to the home setting, where a significant portion of agitation episodes occur, presents a substantial opportunity to address unmet medical needs. Selvaraju views the design parameters of the SERENITY III trial, which will test the safety and efficacy of BXCL501 for at-home use, as well-aligned with expectations and believes the risk is mitigated by the drug’s proven track record in institutional contexts. Furthermore, the financial analyst sees potential in the company’s strategy to advance its TRANQUILITY and SERENITY pivotal programs. The TRANQUILITY In-Care Phase 3 trial aims to evaluate the efficacy and safety of a lower dose of BXCL501 in patients with Alzheimer’s dementia in a care setting, broadening the drug’s potential applications. The established design parameters for these trials, along with the expedited approach the company plans to take, suggest a streamlined path forward that could lead to further label expansions and increased market penetration. Selvaraju’s confidence in BioXcel Therapeutics is reflected in the reiterated Buy rating and the 12-month price target of $10, indicating an optimistic outlook on the company’s growth trajectory. According to TipRanks, Selvaraju is a 4-star analyst with an average return of 6.4% and a 36.00% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as Genmab, BridgeBio Pharma, and MoonLake Immunotherapeutics.

Wow der Kurs hat sich gehalten

Ist bei 2.60 stehen geblieben